The market opportunity lies in providing solutions and services for global medical device companies to comply with US FDA and EU MDR post-market surveillance and complaint handling requirements. This ...

ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, ...

The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable ...

With pressure mounting to shorten timelines and tighten oversight, Flex Databases is betting on a single, configurable ...